Index
S&P 500
Market Cap
121.46B
Enterprise Value
141.41B
Income
5.23B
Sales
37.54B
Book/sh
39.24
Cash/sh
6.89
Employees
95000
IPO
Nov 21, 1977
P/E
23.38
Forward P/E
14.85
PEG
1.92
P/S
3.24
P/B
2.42
P/C
13.77
P/FCF
19.81
EV/EBITDA
13.57
EV/Sales
3.77
Quick Ratio
1.54
Current Ratio
2.07
Debt/Eq
0.56
LT Debt/Eq
0.51
Option/Short
Yes / Yes
EPS (ttm)
4.06
EPS next Y
6.39
EPS next Q
1.33
EPS this Y
8.09%
EPS next Y
6.99%
EPS next 5Y
7.72%
EPS past 3/5Y
9.75% 6.95%
Sales past 3/5Y
5.21% 3.84%
EPS Y/Y TTM
12.28%
Sales Y/Y TTM
9.77%
EPS Q/Q
41.57%
Sales Q/Q
13.73%
Insider Own
0.09%
Insider Trans
-5.67%
Inst Own
88.86%
Inst Trans
-1.94%
ROA
5.68%
ROE
10.66%
ROIC
6.90%
Gross Margin
60.56%
Oper. Margin
19.93%
Profit Margin
13.93%
SMA20
3.48%
SMA50
3.70%
SMA200
7.69%
Trades
Shs Outstand
1.28B
Shs Float
1.28B
52W High
106.33 -10.70%
52W Low
73.31 29.52%
Volatility
2.15% 2.47%
ATR (14)
2.28
RSI (14)
57.69
Beta
0.60
Rel Volume
0.57
Avg Volume
16.35M
Volume
4,261,094
Perf Week
2.06%
Perf Month
9.03%
Perf Quarter
10.78%
Perf Half Y
19.63%
Perf YTD
-1.16%
Perf Year
1.84%
Perf 3Y
36.76%
Perf 5Y
-21.70%
Perf 10Y
15.89%
Prev Close
93.95
Price
94.95
Change %
1.06%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-07-26 Initiated
Barclays
Equal Weight
$95
Aug-27-26 Reiterated
Needham
Buy
$101 → $114
Jul-28-26 Upgrade
UBS
Neutral → Buy
$100
Jun-04-26 Upgrade
BTIG Research
Neutral → Buy
$90
May-21-26 Resumed
Goldman
Neutral
$84
Feb-13-26 Resumed
Barclays
Overweight
$116
Feb-09-26 Upgrade
Needham
Hold → Buy
$121
Feb-03-26 Resumed
Citigroup
Buy
$117
Jan-30-26 Resumed
Wells Fargo
Overweight
$114
Jan-06-26 Upgrade
William Blair
Mkt Perform → Outperform
Nov-19-25 Upgrade
Goldman
Sell → Neutral
$111
Jun-30-25 Upgrade
Wolfe Research
Underperform → Peer Perform
Jun-16-25 Initiated
Leerink Partners
Outperform
$110
Mar-04-25 Upgrade
Citigroup
Neutral → Buy
$92 → $107
Oct-10-24 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$98 → $105
Aug-21-24 Reiterated
Oppenheimer
Perform
$92 → $94
Aug-15-24 Upgrade
UBS
Sell → Neutral
$76 → $90
Aug-14-24 Downgrade
Stifel
Buy → Hold
$100 → $85
May-30-24 Initiated
Goldman
Sell
$83
Jul-19-23 Initiated
Robert W. Baird
Neutral
$90
Show Previous Ratings
Oct-26-26 10:24AM
Oct-23-26 05:53AM
Oct-22-26 07:40AM
07:00AM
Oct-21-26 05:31AM
12:15PM
Loading…
Oct-20-26 12:15PM
Oct-19-26 12:40PM
Oct-16-26 10:25AM
Oct-15-26 05:01PM
04:30PM
03:18PM
10:00AM
10:00AM
09:09AM
Oct-14-26 04:55PM
08:18AM
Loading…
08:18AM
08:00AM
Oct-12-26 04:30PM
01:16PM
12:16PM
08:45AM
Oct-07-26 05:31PM
03:27PM
10:00AM
Oct-06-26 10:02AM
08:18AM
Oct-02-26 03:27PM
04:47AM
Oct-01-26 04:00PM
10:00AM
03:01PM
Loading…
Sep-30-26 03:01PM
09:25AM
09:00AM
05:54AM
Sep-29-26 03:26PM
Sep-28-26 04:33PM
03:09PM
12:49PM
11:30AM
Sep-25-26 10:00AM
07:00AM
Sep-24-26 02:45PM
Sep-22-26 09:40AM
09:29AM
Sep-21-26 11:05AM
Sep-18-26 04:14PM
08:33AM
Sep-17-26 03:06PM
12:31PM
06:43AM
Sep-16-26 03:12PM
11:52AM
06:30AM
Sep-15-26 03:00PM
Sep-14-26 10:34AM
07:33AM
07:30AM
07:30AM
Sep-11-26 02:50PM
08:14AM
Sep-10-26 01:57PM
Sep-09-26 04:22PM
02:06PM
Sep-08-26 06:30AM
Sep-04-26 04:38PM
02:25PM
12:57PM
12:34PM
Sep-03-26 05:06PM
11:24AM
10:37AM
Sep-02-26 03:37PM
01:52PM
09:17AM
07:04AM
Sep-01-26 03:00PM
02:25PM
10:17AM
(Investor's Business Daily)
09:38AM
07:46AM
(The Wall Street Journal)
07:30AM
07:08AM
06:53AM
06:45AM
06:40AM
06:30AM
04:28AM
03:36AM
Aug-31-26 08:47PM
Aug-28-26 03:09PM
Aug-27-26 08:12PM
12:29PM
Aug-26-26 03:51PM
03:31PM
06:48AM
Aug-25-26 12:05PM
11:08AM
Aug-24-26 06:00AM
Aug-21-26 02:01PM
Aug-20-26 04:50PM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Marinaro Michael EVP, Pres MedSurg and Americas Oct 15 '26 Sale 96.00 10,420 1,000,320 105,916 Oct 16 06:02 PM Martha Geoffrey Chairman and CEO Oct 15 '26 Sale 95.00 50,000 4,750,000 277,866 Oct 16 06:00 PM Marinaro Michael Officer Oct 15 '26 Proposed Sale 96.00 10,420 1,000,320 Oct 15 05:00 PM Martha Geoffrey Officer Oct 15 '26 Proposed Sale 95.00 50,000 4,750,000 Oct 15 09:41 AM KIIL HARRY SKIP EVP & President Cardiovascular Sep 16 '26 Sale 93.65 1,483 138,883 42,186 Sep 17 04:17 PM KIIL HARRY SKIP Officer Sep 16 '26 Proposed Sale 93.65 1,483 138,889 Sep 16 02:37 PM Walter Matthew R. SVP, Chief HR Officer Jul 08 '26 Sale 83.15 3,102 257,931 35,694 Jul 09 04:26 PM Walter Matthew R. Officer Jul 08 '26 Proposed Sale 83.15 3,102 257,931 Jul 08 10:15 AM KIIL HARRY SKIP EVP & President Cardiovascular Jun 08 '26 Sale 80.44 4,189 336,965 37,227 Jun 09 04:16 PM KIIL HARRY SKIP Officer Jun 08 '26 Proposed Sale 80.44 4,189 336,965 Jun 08 02:34 PM Walter Matthew R. SVP, Chief HR Officer May 26 '26 Option Exercise 0.00 9,149 0 41,529 May 28 04:26 PM Wall Brett A. EVP & Pres Neuroscience May 26 '26 Option Exercise 0.00 26,907 0 82,183 May 28 04:26 PM Martha Geoffrey Chairman and CEO May 26 '26 Option Exercise 0.00 94,963 0 343,099 May 28 04:25 PM Marinaro Michael EVP, Pres MedSurg and Americas May 26 '26 Option Exercise 0.00 18,994 0 70,593 May 28 04:25 PM KIIL HARRY SKIP EVP & President Cardiovascular May 26 '26 Option Exercise 0.00 15,195 0 48,233 May 28 04:25 PM Blomquist Denise L. Chief Accounting Officer May 26 '26 Option Exercise 0.00 1,712 0 14,974 May 28 04:24 PM KIIL HARRY SKIP EVP & President Cardiovascular Feb 19 '26 Option Exercise 90.90 50,876 4,624,512 85,292 Feb 26 05:48 PM KIIL HARRY SKIP EVP & President Cardiovascular Feb 19 '26 Sale 97.71 52,524 5,132,217 32,768 Feb 26 05:48 PM KIIL HARRY SKIP Officer Feb 19 '26 Proposed Sale 97.71 52,524 5,132,217 Feb 19 03:19 PM Smith Gregory L EVP Global Ops & Supply Chain Nov 19 '25 Sale 101.95 30,000 3,058,451 46,016 Nov 21 04:13 PM Smith Gregory L Officer Nov 19 '25 Proposed Sale 101.95 30,000 3,058,452 Nov 19 11:05 AM
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Galway, Ireland.
Chairman of the Board & CEO Mr. Geoffrey Straub Martha
SVP & Chief Operations and Supply Chain Officer Mr. Rogerio Branco
VP Ms. Denise L. Blomquist
M.Sc. Dr. Laura Mauri M.D.
Vice President & Head of Investor Relations Ms. Ingrid Goldberg